Cargando…

Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer

Poly-ADP ribose polymerase (PARP) inhibitors are constantly increasing in their indications for use as anti-cancer treatment in various neoplasms, the majority of which are linked with BRCA deficiency. Preclinical data support the investigation of PARP inhibitors in other neoplasms exhibiting “BRCAn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papageorgiou, Georgios I., Fergadis, Evangelos, Skouteris, Nikos, Christakos, Evridiki, Tsakatikas, Sergios A., Lianos, Evangelos, Kosmas, Christos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728007/ https://www.ncbi.nlm.nih.gov/pubmed/35004311 http://dx.doi.org/10.3389/fonc.2021.788809

Ejemplares similares

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study
por: Xynogalos, Spyridon, et al.
Publicado: (2022)

Case Report: Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With ATM Mutation
por: Wang, Weiwei, et al.
Publicado: (2022)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Targeting ATM-deficient CLL through interference with DNA repair pathways
por: Knittel, Gero, et al.
Publicado: (2015)

PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Sotirios, Papageorgiou, et al.
Publicado: (2023)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

Atypical ATMs: Broadening the phenotypic spectrum of ATM-associated hereditary cancer
por: Borja, Nicholas A., et al.
Publicado: (2023)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
por: Velazquez, Carolina, et al.
Publicado: (2023)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome
por: File, Danielle M., et al.
Publicado: (2020)

The ATM signaling network in development and disease
por: Stracker, Travis H., et al.
Publicado: (2013)

Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights
por: Kole, Christo, et al.
Publicado: (2022)

Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib
por: Rizvi, Wajeeha, et al.
Publicado: (2017)

Hierarchical bi-directional attention-based RNNs for supporting document classification on protein–protein interactions affected by genetic mutations
por: Fergadis, Aris, et al.
Publicado: (2018)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells
por: de Castro e Gloria, Helena, et al.
Publicado: (2021)

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
por: Qin, Changjiang, et al.
Publicado: (2022)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress
por: Han, Tao, et al.
Publicado: (2022)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
por: Zhang, Hui, et al.
Publicado: (2022)

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials
por: Luo, Zhanyang, et al.
Publicado: (2023)

Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors
por: Herath, Nirmitha I., et al.
Publicado: (2019)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
por: Schettini, Francesco, et al.
Publicado: (2021)

Prevalence of ATM Sequence Variants in Northern Plains American Indian Cancer Patients
por: Petereit, Daniel G., et al.
Publicado: (2013)

Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
por: Jiang, Yi-Ling, et al.
Publicado: (2023)

SPAK Deficiency Attenuates Chemotherapy-Induced Intestinal Mucositis
por: Huang, Tien-Yu, et al.
Publicado: (2021)

Novel targets for ATM-deficient malignancies
por: Winkler, Johannes, et al.
Publicado: (2014)

DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination
por: Merlini, Alessandra, et al.
Publicado: (2022)

Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
por: Zhou, Taotao, et al.
Publicado: (2022)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
por: Botrus, Gehan, et al.
Publicado: (2022)

End to end comparison of surface‐guided imaging versus stereoscopic X‐rays for the SRS treatment of multiple metastases with a single isocenter using 3D anthropomorphic gel phantoms
por: Bry, Victoria, et al.
Publicado: (2022)

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
por: Franzese, Elisena, et al.
Publicado: (2019)

Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
por: Li, Caixia, et al.
Publicado: (2022)

BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report
por: Chen, Zhujun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p72dh0s9dk71563qh6fn4ufctv